Clinical Research of ROBO1 Specific BiCAR-NK/T Cells on Patients With Malignant Tumor

Summary

Immunotherapy has become the major breakthrough and the most promising treatment, with the host of development of tumor biology, molecular biology and immunology. ROBO1 is a potential target and spectacular paradigm in the diagnosis and treatment of solid tumors. This study is for evaluation of the safety and efficacy of ROBO1 CAR-NK/T cell immunotherapy for malignant tumors.

Timeline

Start

2019-05

Primary completion

2021-05

Completion

2022-05

Drugs

Indications